SCHEMBL7102186

SCHEMBL7102186

CCOC(=O)CCCCCc1ccc(OC)nc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4Z1 Q86W10 2/20 0.48
CYP4F2 P78329 2/20 0.46
CYP4A11 Q02928 2/20 0.46
TBXAS1 P24557 1/20 0.46
CYP4F11 Q9HBI6 1/20 0.43
CYP4F12 Q9HCS2 1/20 0.43
ALOX5 P09917 1/20 0.41
PPARG P37231 1/20 0.41
PPARA Q07869 1/20 0.41
SYK P43405 1/20 0.40
TDP1 Q9NUW8 2/20 0.40
FFAR4 Q5NUL3 1/20 0.40
GAA P10253 1/20 0.40
MAPK1 P28482 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
LTA4H P09960 1/20 0.40
KDM4E B2RXH2 1/20 0.40
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29702259 0.89 CYP4F2 (0.56) CYP4Z1CYP4F2CYP4A11SYKKDM4E
SCHEMBL6307266 0.89 CYP4F2 (0.56) CYP4Z1CYP4F2CYP4A11SYKKDM4E
SCHEMBL7099963 0.82 CYP4F2 (0.46) CYP4Z1CYP4F2CYP4A11TBXAS1CYP4F11
SCHEMBL9671800 0.81 CYP4Z1 (0.65) CYP4Z1CYP4F2CYP4A11TBXAS1CYP4F11
SCHEMBL6665672 0.81 CYP4Z1 (0.50) CYP4Z1CYP4F2CYP4A11TBXAS1CYP4F11
SCHEMBL5298324 0.80 CYP4F2 (0.49) CYP4Z1CYP4F2CYP4A11TBXAS1CYP4F11
SCHEMBL27956494 0.80 JAK2 (0.45) CYP4Z1TBXAS1KDM4EMEN1ALDH1A1
SCHEMBL29852292 0.80 NFKB1 (0.65) CYP4Z1CYP4F2CYP4A11TBXAS1CYP4F11
SCHEMBL3675681 0.79 ALOX5 (0.57) CYP4Z1CYP4F2CYP4A11CYP4F11CYP4F12
SCHEMBL19236921 0.78 CASP3 (0.57) TBXAS1PPARGPPARATDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1229910-A4 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO INC (US) 2003-10-01 EP disclosed
EP-1229910-A1 INTEGRIN RECEPTOR ANTAGONISTS Merck & Co., Inc. (US) 2002-08-14 EP disclosed
US-6413955-B1 1,8-NAPHTHYRIDINES OR 5-THIO-1,8-NAPHTHYRIDINES OR 5-OXO-1,8-NAPHTHYRIDINES; BONE RESORPTION, OSTEOPOROSIS, VASCULAR REST-ENOSIS, DIABETIC RETINOPATHY, MACULAR DEGENERATION, ANGIO-GENESIS, ATHEROSCLEROSIS, INFLAMMATORY ARTHRITIS, CANCER MERCK & CO., INC. 2002-07-02 US disclosed
WO-2001024797-A1 INTEGRIN RECEPTOR ANTAGONISTS MERCK & CO., INC. (US) 2001-04-12 WO disclosed